{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:13:05Z","timestamp":1792793585220,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.intimp.2024.113906","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T05:59:07Z","timestamp":1736056747000},"page":"113906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Inhibition of SIRT4 promotes bladder cancer progression and immune escape via attenuating CD8+ T cells function"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1438-3126","authenticated-orcid":false,"given":"Jiancheng","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Nat. Cancer Center"},{"issue":"5","key":"10.1016\/j.intimp.2024.113906_b0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2024.113906_b0020","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"3","key":"10.1016\/j.intimp.2024.113906_b0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/iju.15338","article-title":"Urinary markers for bladder cancer diagnosis: A review of current status and future challenges","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.intimp.2024.113906_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arr.2017.08.001","article-title":"Sirtuins, epigenetics and longevity","volume":"40","author":"W\u0105troba","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.intimp.2024.113906_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-biochem-082520-125411","article-title":"Understanding the function of mammalian sirtuins and protein lysine acylation","volume":"90","author":"Wang","year":"2021","journal-title":"Annu. Rev. Biochem"},{"issue":"13","key":"10.1016\/j.intimp.2024.113906_b0040","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2013.120","article-title":"Sorting out functions of sirtuins in cancer","volume":"33","author":"Roth","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2024.113906_b0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","article-title":"Mammalian sirtuins: biological insights and disease relevance","volume":"5","author":"Haigis","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.intimp.2024.113906_b0050","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.2147\/OTT.S157724","article-title":"Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer","volume":"11","author":"Huang","year":"2018","journal-title":"OncoTargets Therapy"},{"issue":"5","key":"10.1016\/j.intimp.2024.113906_b0055","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2006.06.057","article-title":"SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells","volume":"126","author":"Haigis","year":"2006","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2024.113906_b0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2017.03.003","article-title":"SIRT4 is a lysine deacylase that controls leucine metabolism and insulin secretion","volume":"25","author":"Anderson","year":"2017","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13008-023-00091-w","article-title":"SIRT4 is an independent prognostic factor in bladder cancer and inhibits bladder cancer growth by suppressing autophagy","volume":"18","author":"Yin","year":"2023","journal-title":"Cell Div"},{"issue":"5","key":"10.1016\/j.intimp.2024.113906_b0070","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1021\/acs.jproteome.9b00086","article-title":"Mitochondrial function, metabolic regulation, and human disease viewed through the prism of sirtuin 4 (SIRT4) functions","volume":"18","author":"Betsinger","year":"2019","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0075","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1038\/s41598-022-16610-8","article-title":"SIRT4 functions as a tumor suppressor during prostate cancer by inducing apoptosis and inhibiting glutamine metabolism","volume":"12","author":"Cai","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113906_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216064","article-title":"The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer","volume":"556","author":"Jiang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2024.113906_b0085","article-title":"SIRT4 is associated with microvascular infiltration, immune cell infiltration, and epithelial mesenchymal transition in hepatocellular carcinoma","volume":"18794","author":"Li","year":"2024","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.intimp.2024.113906_b0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.intimp.2024.113906_b0095","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41419-021-03901-7","article-title":"VHL regulates the sensitivity of clear cell renal cell carcinoma to SIRT4-mediated metabolic stress via HIF-1\u03b1\/HO-1 pathway","volume":"12","author":"Tong","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2024.113906_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7095902","article-title":"NOX2-derived reactive oxygen species in cancer","volume":"2020","author":"Grauers Wiktorin","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.intimp.2024.113906_b0105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/imm.13123","article-title":"Sirtuin4 suppresses the anti-neuroinflammatory activity of infiltrating regulatory T cells in the traumatically injured spinal cord","volume":"158","author":"Lin","year":"2019","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.intimp.2024.113906_b0110","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2024.113906_b0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","article-title":"CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond","volume":"11","author":"Karin","year":"2020","journal-title":"Front. Immunol."},{"issue":"10064","key":"10.1016\/j.intimp.2024.113906_b0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","article-title":"NAD(+) metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2024.113906_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2018.11.003","article-title":"The roles of sirtuins family in cell metabolism during tumor development","volume":"57","author":"Zhu","year":"2019","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0135","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2024.113906_b0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fonc.2020.00474","article-title":"Sirt4: A multifaceted enzyme at the crossroads of mitochondrial metabolism and cancer","volume":"10","author":"Tomaselli","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13046-020-01613-y","article-title":"HIF-1\u03b1-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4","volume":"39","author":"Yu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"key":"10.1016\/j.intimp.2024.113906_b0150","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fendo.2018.00783","article-title":"The roles of mitochondrial SIRT4 in cellular metabolism","volume":"9","author":"Min","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113906_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2024.100029","article-title":"Mitochondrial sirtuins: Energy dynamics and cancer metabolism","volume":"47","author":"Lee","year":"2024","journal-title":"Mol. Cells"},{"key":"10.1016\/j.intimp.2024.113906_b0160","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.2147\/CMAR.S172509","article-title":"Tumor-suppressive function of SIRT4 in neuroblastoma through mitochondrial damage","volume":"10","author":"Wang","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.intimp.2024.113906_b0165","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.2147\/OTT.S156143","article-title":"SIRT4 acts as a tumor suppressor in gastric cancer by inhibiting cell proliferation, migration, and invasion","volume":"11","author":"Sun","year":"2018","journal-title":"OncoTargets Therapy"},{"key":"10.1016\/j.intimp.2024.113906_b0170","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2147\/OTT.S189536","article-title":"SIRT4 inhibits the proliferation, migration, and invasion abilities of thyroid cancer cells by inhibiting glutamine metabolism","volume":"12","author":"Chen","year":"2019","journal-title":"OncoTargets Therapy"},{"key":"10.1016\/j.intimp.2024.113906_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol., Immunotherapy: CII"},{"key":"10.1016\/j.intimp.2024.113906_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104458","article-title":"SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4\/CXCL12 axis","volume":"371","author":"Fang","year":"2022","journal-title":"Cell. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113906_b0190","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2022.02.030","article-title":"Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis","volume":"77","author":"Sun","year":"2022","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113906_b0195","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.cmet.2020.07.008","article-title":"Sirt2 inhibition enhances metabolic fitness and effector functions of tumor-reactive T cells","volume":"32","author":"Hamaidi","year":"2020","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0200","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41392-023-01314-w","article-title":"SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation","volume":"8","author":"Yi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113906_b0205","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41392-021-00801-2","article-title":"An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity","volume":"6","author":"Wei","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"17","key":"10.1016\/j.intimp.2024.113906_b0210","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.7150\/thno.100667","article-title":"Targeting sirtuins for cancer therapy: epigenetics modifications and beyond","volume":"14","author":"Shen","year":"2024","journal-title":"Theranostics."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924024287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924024287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:23:55Z","timestamp":1740111835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924024287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"alternative-id":["S1567576924024287"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113906","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of SIRT4 promotes bladder cancer progression and immune escape via attenuating CD8+ T cells function","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113906"}}